Clinical Trial

TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a multi-institutional pilot trial for patients with advanced breast cancer. The trial is designed to assess the safety and tolerability of induction talazoparib followed by combination of talazoparib and avelumab. As an exploratory endpoint, the study team will evaluate the immunomodulatory effects of induction talazoparib followed by the combination of talazoparib and avelumab in patients with advanced breast cancer.
Protocol Amendment History 15 amendments
This ClinicalTrials.gov record has been amended 15 times since 2019-05-24; most recent amendment 2026-04-03.
Status change: Recruiting → Active, Not Recruiting 2022-10-10
Trial Details
NCT Number NCT03964532
Lead Sponsor Georgetown University
Collaborators: Pfizer
Conditions Breast Cancer
Enrollment 24 participants
Start Date 2019-04-17
Primary Completion 2027-04 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2026-04-09